Ablumir
Built Around Immunology

# Anti-VEGF Receptor 1 Rabbit mAb [27F84]

**Catalog No.: A52120**

## Basic Information

| | |
|---|---|
| Catalog No. (Cat.No.) | A52120 |
| Host species | Rabbit |
| Reactivity | Human,Mouse,Rat |
| Applications | WB,IHC,IP,IF,ELISA |
| Synonyms | VEGF Receptor 1,VEGFR1,VEGFR-1,fms-like tyrosine kinase 1,Flt-1,CD308 |

## Product Information

| | |
|---|---|
| Target | VEGF Receptor 1 |
| Molecular Weight(Calculated) | 151 kDa |
| Molecular Weight(Observed) | 180 kDa |
| Isotype | IgG,Kappa |
| Conjugation | NA |
| Concentration | 0.2 mg/ml |
| Clonality | Monoclonal |
| Clone No. | 27F84 |
| RRID | NA |
| Storage buffer | 50% Glycerol, 0.05% BSA and 0.05% preservative in PBS (pH 7.2-7.4) |
| Storage | Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles. |
| Shipped at conditions | Frozen |
| Form | Liquid |

Ablumir
Built Around Immunology

## Product Usage Information

| Application | Dilution |
|---|---|
| WB | 1:1000-1:5000 |
| IHC | 1:200-1:1000 |
| IP | 1:50-1:200 |
| IF | 1:200-1:1000 |
| ELISA | 1:5000-1:20000 |

## Target Information

| | |
|---|---|
| Protein Name | Vascular endothelial growth factor receptor-1 |
| Gene Name | *FLT1* |
| Domain | NA |
| Background | VEGFR1 (Vascular Endothelial Growth Factor Receptor 1) is an essential transmembrane receptor protein belonging to the tyrosine kinase receptor family. It is predominantly expressed on vascular endothelial cells, monocytes and macrophages, and mainly regulates angiogenesis, endothelial homeostasis and inflammatory immune responses in the human body. By specifically binding to VEGF ligands, this target activates downstream PI3K and MAPK signaling cascades, thereby modulating endothelial cell proliferation, migration, differentiation and vascular permeability to maintain normal vascular development and microcirculation balance. Abnormal activation or overexpression of VEGFR1 induces pathological angiogenesis, increases vascular permeability and promotes inflammatory cell infiltration, continuously driving tumor microenvironment remodeling, ocular vascular lesions and chronic inflammatory diseases. As a core target of anti-angiogenic targeted drugs, VEGFR1 can be specifically recognized and blocked by anti-VEGFR1 rabbit monoclonal antibodies to inhibit abnormal vascular proliferation and inflammation, which exerts precise therapeutic effects and has broad clinical application prospects in tumor and vascular disease treatment. |